Therefore, it seems to be reasonable to assume that mainly pituitary tumors with elevated proliferation rates and high EZH2 expression (e.g. atypical PA and pituitary carcinomas) may benefit from its inhibition. Here, EZH2 is linked to pituitary adenocarcinoma.